These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22568867)

  • 1. Nestin expression identifies ependymoma patients with poor outcome.
    Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
    Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.
    Nambirajan A; Sharma MC; Gupta RK; Suri V; Singh M; Sarkar C
    Neuropathol Appl Neurobiol; 2014 Oct; 40(6):714-25. PubMed ID: 24224478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical markers for prognosis of ependymal neoplasms.
    Korshunov A; Golanov A; Timirgaz V
    J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic marker analysis in pediatric intracranial ependymomas.
    McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
    J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
    Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
    Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
    Korshunov A; Golanov A; Timirgaz V
    J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
    Chen C; Chen L; Yao Y; Qin Z; Chen H
    J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
    Modena P; Buttarelli FR; Miceli R; Piccinin E; Baldi C; Antonelli M; Morra I; Lauriola L; Di Rocco C; Garrè ML; Sardi I; Genitori L; Maestro R; Gandola L; Facchinetti F; Collini P; Sozzi G; Giangaspero F; Massimino M
    Neuro Oncol; 2012 Nov; 14(11):1346-56. PubMed ID: 23076205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.
    Cage TA; Clark AJ; Aranda D; Gupta N; Sun PP; Parsa AT; Auguste KI
    J Neurosurg Pediatr; 2013 Jun; 11(6):673-81. PubMed ID: 23540528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
    Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
    Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
    Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T
    Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of localization and grading in intracranial ependymomas of childhood.
    Ernestus RI; Schröder R; Stützer H; Klug N
    Childs Nerv Syst; 1996 Sep; 12(9):522-6. PubMed ID: 8906366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of spinal ependymomas: an institutional experience over 25 years in 134 patients.
    Tarapore PE; Modera P; Naujokas A; Oh MC; Amin B; Tihan T; Parsa AT; Ames CP; Chou D; Mummaneni PV; Weinstein PR
    Neurosurgery; 2013 Aug; 73(2):247-55; discussion 255. PubMed ID: 23670032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
    Korshunov A; Sycheva R; Timirgaz V; Golanov A
    J Neurooncol; 1999; 45(3):219-27. PubMed ID: 10845392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.